Where will you go next? (Injector) - 2024

How EMPAVELI can help | LDH

Changes in LDH with EMPAVELI

Rapid and sustained LDH reductions with EMPAVELI vs control arm—in people who had never received a complement inhibitor One of the primary goals in the PRINCE study: to explore whether EMPAVELI reduced LDH in people living with PNH not previously treated with a complement inhibitor By Week 2 in PRINCE, average LDH levels in the EMPAVELI group had dropped from baseline and remained there through 26 weeks.

Louis is an adult with PNH who's taken EMPAVELI.

In people who had never received a complement inhibitor (PRINCE)

4000

3000

1535

2151

2000

1946

1000

400

205

(P <0.0001)

200

Normal range of LDH levels

0

Week 6

Week 12

Week 18

Week 26

34

33

33

34 30 7 5

EMPAVELI n Control arm n *

35 32 33 33 33 34 34 34 34 1817171713 9 8 8 8

7

8

6

Control arm (excluding complement inhibitors)

EMPAVELI

*Control arm (excluding complement inhibitors) only includes data on or before escape (switching to EMPAVELI).

At Week 26, average reductions in LDH levels were:  -1870 U/L in the EMPAVELI group

 -400 U/L in the control arm (excluding complement inhibitors)

IMPORTANT SAFETY INFORMATION (cont’d) If you stop taking EMPAVELI, your healthcare provider will need to monitor you closely for at least 8 weeks after stopping EMPAVELI. Stopping treatment with EMPAVELI may cause a breakdown of red blood cells due to PNH. Symptoms or problems that can happen due to red blood cell breakdown include:  decreased hemoglobin level in your blood

Changes in LDH levels with EMPAVELI vs eculizumab— in people who had previously received a C5i (PEGASUS) At Week 16 in PEGASUS, it could not be determined if EMPAVELI was any worse than C5i (eculizumab) in reducing LDH.

 tiredness  pain in the stomach (abdomen)  blood clots  erectile dysfunction (ED)

C5i=C5 inhibitor; LDH=lactate dehydrogenase; PNH=paroxysmal nocturnal hemoglobinuria; SE=standard error.

 blood in your urine  shortness of breath  trouble swallowing

Please see full Important Safety Information, including Boxed WARNING regarding risk of serious infections, on pages 38-39, and the full Prescribing Information and Medication Guide.

16

17

Made with FlippingBook - professional solution for displaying marketing and sales documents online